Fairhurst-Hunter, Zammy
Walters, Robin G.
Zink, Alexander
Lin, Kuang
Guo, Yu
Yu, Canqing
Lv, Jun
Li, Liming
Freitag, Daniel F.
Chen, Zhengming
Millwood, Iona Y.
Funding for this research was provided by:
Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z)
GlaxoSmithKline
Medical Research Council (MC-PC-13049, MC-PC-14135, MC_UU_00017/1, MC_UU_12026/2, MC_U137686851)
Cancer research UK (C16077/A29186, C500/A16896)
British heart foundation (CH/1996001/9454)
National Natural Science Foundation of China (91843302)
National Key Research and Development Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504, 2016YFC1303904)
Bayer
Article History
Received: 8 February 2022
Accepted: 13 April 2022
First Online: 5 May 2022
Declarations
:
: The China Kadoorie Biobank (CKB) complies with all the required ethical standards for medical research on human subjects. Ethical approvals were granted and have been maintained by the relevant institutional ethical research committees in the UK and China. Informed consent was obtained from all participants included in the study. No animal studies were carried out by the authors for this article.
: Drs. Freitag and Zink are employees of Bayer AG. No other disclosures were reported.